Form 4: CEO Leon O. Moulder Jr. Receives Zenas BioPharma Options
Statement of Changes in Beneficial Ownership
Zenas BioPharma CEO Leon O. Moulder Jr. was granted 500,000 stock options with an exercise price of $18.71.
Summary
- CEO Leon O. Moulder Jr. received a grant of 500,000 stock options on June 15, 2026.
- The options have an exercise price of $18.71 per share.
- The options are set to expire on June 15, 2036.
- Vesting follows a standard four-year schedule: 25% on the first anniversary and equal monthly installments over the subsequent 36 months.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard executive compensation practices.
Positives
- Alignment of executive interests with long-term shareholder value through equity-based compensation.
Negatives
- Potential for future shareholder dilution upon the exercise of these options.
Risks
- Continued service requirement for full vesting of the 500,000 option grant.
Future Outlook
The grant indicates management's long-term commitment to the company's growth trajectory over the next decade.
Management Comments
- The filing does not contain specific narrative comments from management beyond the required disclosure of the transaction.
Industry Context
StockSavvy.ai notes that equity grants for C-suite executives in the biotechnology sector are standard practice to incentivize long-term R&D and clinical development milestones.
Comparison to Industry Standards
- The four-year vesting schedule is consistent with standard corporate governance practices for executive equity compensation in the U.S. biotech industry.
Stakeholder Impact
- Shareholders may experience minor dilution if these options are exercised in the future.
Next Steps
- Vesting of 25% of the options on June 15, 2027.
Key Dates
| Date | Description |
|---|---|
| 06/15/2026 | Transaction date of the stock option grant. |
| 06/15/2027 | Initial vesting date for 25% of the granted options. |
| 06/15/2036 | Expiration date of the granted stock options. |
Keywords
Zenas BioPharma, ZBIO, Form 4, Insider Trading, Stock Options, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.